Merus N.V. (MRUS) News
Filter MRUS News Items
MRUS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRUS News Highlights
- For MRUS, its 30 day story count is now at 3.
- Over the past 23 days, the trend for MRUS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest MRUS News From Around the Web
Below are the latest news stories about MERUS NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.
Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 53% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a BetThe mean of analysts' price targets for Merus N.V. (MRUS) points to an 87.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Merus N.V. (MRUS) Moves to Buy: Rationale Behind the UpgradeMerus N.V. (MRUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-129 from ongoing expansion cohorts in non-small cell lung cancer (NSCLC) and in previous |
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023- Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT - Poster presentation on MCLA-129 in previously treated HNSCC on Saturday, December 2 at 17:50 p.m. SGT - Investor call on Monday, November 27, 2023 8:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company deve |
Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 85.4% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 83.26%: Read This Before Placing a BetThe consensus price target hints at an 83.3% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update– Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 2024 – Zeno interim clinical data continue to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions – Based on the Company’s current operating plan and recent oversubscribed public offering raising approximately $172M gross proceeds, existing cash, cash equivalents and marketable securit |
Merus to Participate in Upcoming Investor ConferencesUTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: BMO Biopharma Spotlight Series: Oncology Day (fireside chat): Wednesday, November 8 at 11:30-11:55 a.m. ET (No live webcast, |
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |